Changing antimicrobial resistance profiles of Burkholderia cepacia in hospitals across China:results from CHINET Antimicrobial Resistance Surveillance Program,2015-2021
- VernacularTitle:2015-2021年CHINET临床分离洋葱伯克霍尔德菌耐药性变迁
- Author:
Chunyue GE
1
;
Yunjian HU
;
Xiaoman AI
;
Yang YANG
;
Fupin HU
;
Demei ZHU
;
Yingchun XU
;
Xiaojiang ZHANG
;
Hui LI
;
Ping JI
;
Yi XIE
;
Mei KANG
;
Chuanqing WANG
;
Pan FU
;
Yuanhong XU
;
Ying HUANG
;
Ziyong SUN
;
Zhongju CHEN
;
Yuxing NI
;
Jingyong SUN
;
Yunzhuo CHU
;
Sufei TIAN
;
Zhidong HU
;
Jin LI
;
Yunsong YU
;
Jie LIN
;
Bin SHAN
;
Yan DU
;
Sufang GUO
;
Lianhua WEI
;
Fengmei ZOU
;
Hong ZHANG
;
Chun WANG
;
Chao ZHUO
;
Danhong SU
;
Dawen GUO
;
Jinying ZHAO
;
Hua YU
;
Xiangning HUANG
;
Wen'en LIU
;
Yanming LI
;
Yan JIN
;
Chunhong SHAO
;
Xuesong XU
;
Chao YAN
;
Shanmei WANG
;
Yafei CHU
;
Lixia ZHANG
;
Juan MA
;
Shuping ZHOU
;
Yan ZHOU
;
Lei ZHU
;
Jinhua MENG
;
Fang DONG
;
Zhiyong LÜ
;
Fangfang HU
;
Han SHEN
;
Wanqing ZHOU
;
Wei JIA
;
Gang LI
;
Jinsong WU
;
Yuemei LU
;
Jihong LI
;
Jinju DUAN
;
Jianbang KANG
;
Xiaobo MA
;
Yanping ZHENG
;
Ruyi GUO
;
Yan ZHU
;
Yunsheng CHEN
;
Qing MENG
;
Shifu WANG
;
Xuefei HU
;
Jilu SHEN
;
Wenhui HUANG
;
Ruizhong WANG
;
Hua FANG
;
Bixia YU
;
Yong ZHAO
;
Ping GONG
;
Kaizhen WENG
;
Yirong ZHANG
;
Jiangshan LIU
;
Longfeng LIAO
;
Hongqin GU
;
Lin JIANG
;
Wen HE
;
Shunhong XUE
;
Jiao FENG
;
Chunlei YUE
Author Information
- Publication Type:Journal Article
- Keywords: Burkholderia cepacia; resistance rate; ceftazidime; meropenem; minocycline; levofloxacin; trimethoprim-sulfamethoxazole
- From: Chinese Journal of Infection and Chemotherapy 2025;25(5):557-562
- CountryChina
- Language:Chinese
- Abstract: Objective To examine the changing prevalence and antimicrobial resistance profiles of Burkholderia cepacia in 52 hospitals across China from 2015 to 2021.Methods A total of 9 261 strains of B.cepacia were collected from 52 hospitals between January 1,2015 and December 31,2021.Antimicrobial susceptibility of the strains was tested using Kirby-Bauer method or automated antimicrobial susceptibility testing systems according to a unified protocol.The results were interpreted according to the breakpoints released in the Clinical & Laboratory Standards Institute(CLSI)guidelines(2023 edition).Results A total of 9 261 strains of B.cepacia were isolated from all age groups,especially elderly patients.The proportion was 11.1％(1 032 strains)in children,significantly lower than the proportion in adults.About half(46.5％,4 310/9 261)of the strains were isolated from patients at least 60 years old and 42.3％(3 919/9 261)of the strains were isolated from young adults.Most isolates(71.1％)were isolated from sputum and respiratory secretions,followed by urine(10.7％)and blood samples(8.1％).B.cepacia isolates were highly susceptible to the five antimicrobial agents recommended in the CLSI M100 document(33rd edition,2023).B.cepacia isolates showed relatively higher resistance rates to meropenem and levofloxacin.However,the resistance rates to ceftazidime,trimethoprim-sulfamethoxazole,and minocycline remained below 8.1％.The percentage of B.cepacia strains resistant to levofloxacin was the highest compared to other antibiotics in any of the three age groups(from 12.4％in the patients＜18 years old to 20.6％in the patients aged 60 years or older).Conclusions B.cepacia is one of the clinically important non-fermenting gram-negative bacteria.Accurate and timely reporting of antimicrobial susceptibility test results and ongoing antimicrobial resistance surveillance are helpful for rational prescription of antimicrobial agents and proper prevention and control of nosocomial infections.
